Analysts have been eager to weigh in on the Healthcare sector with new ratings on Miragen Therapeutics Inc (NASDAQ:MGEN) and Bluebird Bio (NASDAQ:BLUE).
Miragen Therapeutics Inc (MGEN)
Oppenheimer analyst Leah R. Cann maintained a Buy rating on Miragen Therapeutics Inc today and set a price target of $19. The company’s shares closed on Friday at $6.38, close to its 52-week low of $5.01.
Cann wrote:
“miRagen has a pipeline of two experimental clinical therapies. The first anticipated commercial impact is from MRG-106 (cobomarsen) in 2022. Leukemia & Lymphoma Society (LLS) is not only important as a source of funding, but also for patient awareness of the SOLAR study, which could aid in enrollment. This is encouraging for a faster registration path for CTCL. We estimate that MiRagen’s operating losses will continue until the launch of MRG-106 in 2022, when we estimate the company will turn profitable as revenue starts to meaningfully offset losses.”
According to TipRanks.com, Cann is a 5-star analyst with an average return of 21.3% and a 55.6% success rate. Cann covers the Healthcare sector, focusing on stocks such as CytomX Therapeutics Inc, Crispr Therapeutics AG, and Syros Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Miragen Therapeutics Inc with a $18.83 average price target.
See today’s analyst top recommended stocks >>
Bluebird Bio (BLUE)
In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Sell rating on Bluebird Bio, with a price target of $122. The company’s shares closed on Friday at $150.
Piros noted:
“We rate bluebird bio Underweight. BLUE, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for rare severe genetic diseases. Its product candidates include Lenti-D, which is in a pivotal clinical study for the treatment of cerebral adrenoleukodystrophy; LentiGlobin, which is in Phase 1/2 clinical studies for the treatment of beta thalassemia major and severe sickle cell disease (SCD); and bb2121 and bb21217 CAR-T candidates in multiple myeloma. Valuation Summary We value bluebird bio based on a risk-adjusted NPV calculation of its clinical pipeline.”
According to TipRanks.com, Piros has 0 stars on 0-5 star ranking scale with an average return of -8.2% and a 37.6% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
Bluebird Bio has an analyst consensus of Moderate Buy, with a price target consensus of $217.30.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
